Union européenne - français - EMA (European Medicines Agency)

bavarian nordic a/s - virus de la vaccine modifié ankara - bavarian nordic (mva-bn) - smallpox vaccine; monkeypox virus - d'autres vaccins viraux, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 et 5. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Canada - français - Health Canada

bavarian nordic as - virus modifié de la vaccine (ankara-bavarian nordic) - suspension - 50000000dict50 - virus modifié de la vaccine (ankara-bavarian nordic) 50000000dict50 - vaccines

Union européenne - français - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - la dengue - vaccins - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 et 4. l'utilisation de dengvaxia doit être en conformité avec les recommandations officielles.

Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - fièvre hémorragique À virus ebola - vaccins - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - rvsvdeltag-zebov-gp vivus attenuatum - solution injectable - rvsvdeltag-zebov-gp vivus attenuatum >7.2 mio u., trometamolum, albuminum humanum, aqua ad iniectabile, q.s. ad solutionem pro 1 ml. - ervebo ist indiziert für die aktive immunisierung von personen ab 18 jahren zum schutz vor der ebola-viruskrankheit (evd [ebola virus disease]), die durch das zaire-ebola-virus verursacht wird - les vaccins

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - sars cov-2 rs nvx-cov2373 - injektionsdispersion - sars cov-2 rs nvx-cov2373 5 µg, adjuvans matrix-m: saponinum fraction-a 42.5 µg et saponinum fraction-c 7.5 µg ex quillaja saponariae molina extractum purificatum, cholesterolum, phosphatidylcholinum, int-rac-alpha-tocopherolum, kalii dihydrogenophosphas, kalii chloridum, dinatrii phosphas dihydricus, dinatrii phosphas heptahydricus, natrii dihydrogenophosphas monohydricus, natrii chloridum, polysorbatum 80, natrii hydroxidum q.s. ad ph, acidum hydrochloridum q.s. ad ph, aqua ad iniectabile q.s. ad praeparationem pro 0.5 ml corresp., natrium 4.0 mg, kalium 0.003 mg. - aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus verursachten coronavirus-2019-erkrankung (covid-19) ab 12 jahren - les vaccins

Union européenne - français - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccins - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Canada - français - Health Canada

merck canada inc - vaccin contre le virus ebola zaïre (rvsv [delta] g-zebov-gp, vivant) - solution - 72000000ufp - vaccin contre le virus ebola zaïre (rvsv [delta] g-zebov-gp, vivant) 72000000ufp

Union européenne - français - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - la dengue - vaccins - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

moderna switzerland gmbh - imelasomeranum, elasomeranum - seringue préremplie - suspension: imelasomeranum 0.025 mg pro dosi, elasomeranum 0.025 mg pro dosi, heptadecan-9-ylis 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)-octanoas pro dosi, cholesterolum pro dosi, 1,2-distearoyl-sn-glycero-3-phosphocholinum pro dosi, 1,2-dimyristoyl-rac-glycero-3-polyethylenglycoli 2000 aether methylicus pro dosi, trometamolum pro dosi, trometamoli hydrochloridum pro dosi, acidum aceticum pro dosi, natrii acetas trihydricus pro dosi, saccharum pro dosi, aqua ad iniectabile, pro dosi. - spikevax bivalent original / omicron ist für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus verursachten coronavirus-2019-erkrankung (covid-19) bei personen ab 18 jahren indiziert. - les vaccins